Intraoperative high-dose dexamethasone for cardiac surgery: a randomized controlled trial

Area of Science:

• Cardiology
• Anesthesiology
• Critical Care Medicine

Background:

• Corticosteroids are used in cardiac surgery to reduce inflammation from cardiopulmonary bypass and surgical trauma.
• Evidence for routine corticosteroid use preventing major adverse events is limited.

Purpose of the Study:

• To determine if intraoperative high-dose dexamethasone reduces major adverse events in patients undergoing cardiac surgery.
• To quantify the impact of dexamethasone on key clinical outcomes.

Main Methods:

• Multicenter, randomized, double-blind, placebo-controlled trial involving 4494 adult patients.
• Patients received either a single intraoperative dose of dexamethasone (1 mg/kg) or a placebo.
• Primary outcome was a composite of death, myocardial infarction, stroke, renal failure, or respiratory failure within 30 days.

Main Results:

• The primary composite outcome occurred in 7.0% of the dexamethasone group vs. 8.5% of the placebo group (RR, 0.83; 95% CI, 0.67-1.01; P = .07).
• Dexamethasone was associated with decreased postoperative infection, shorter mechanical ventilation duration, and reduced ICU/hospital stays.
• Higher postoperative glucose levels were observed in the dexamethasone group.

Conclusions:

• Intraoperative dexamethasone did not significantly reduce the 30-day incidence of major adverse events in adults undergoing cardiac surgery.
• Dexamethasone may offer benefits in reducing certain complications but does not impact the overall composite major adverse event rate.